DRONEDARONE HYDROCHLORIDE (dronedarone hydrochloride) by Teva is unknown. Approved for hospitalization for atrial fibrillation (af) in patients in sinus rhythm with a history of paroxysmal, persistent af (. First approved in 2024.
Drug data last refreshed 18h ago
unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.
Worked on DRONEDARONE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.